Table 3. Baseline characteristics of 4 stages of chronic kidney disease .
| Total (N = 512) | CKD stage 1 (n = 163) | CKD stage 2 (n = 171) | CKD stage 3 (n = 136) | CKD stage 4 (n = 42) | p value | |
| Patient characteristics | ||||||
| Age (year) | 60.6 ± 14.2 | 47.6 ± 8.9 | 60.1 ± 9.6 | 73.3 ± 9.4 | 71.7 ± 14.2 | < 0.001 |
| Body weight (kilogram) | 69.7 ± 12.8 | 78.5 ± 11.2 | 70.3 ± 10.3 | 61.5 ± 10.5 | 59.5 ± 10.1 | < 0.001 |
| Male gender | 451 (88.1%) | 153 (93.9%) | 153 (89.5%) | 116 (85.3%) | 29 (69%) | < 0.001 |
| Hypertension | 281 (54.9%) | 71 (43.6%) | 101 (59.1%) | 79 (58.1%) | 30 (71.4%) | 0.002 |
| Diabetes mellitus | 148 (28.9%) | 34 (20.9%) | 51 (29.8%) | 43 (31.6%) | 20 (47.6%) | 0.01 |
| Current smoking | 273 (53.3%) | 106 (65%) | 96 (56.1%) | 59 (43.4%) | 12 (28.6%) | < 0.001 |
| Previous cardiovascular event | 35 (6.8%) | 5 (3%) | 10 (5.8%) | 14 (10.3%) | 6 (3.7%) | 0.02 |
| Laboratory data | ||||||
| Total cholesterol concentration (mg/dl) | 182.4 ± 43.9 | 196.1 ± 44.8 | 186.1 ± 40.5 | 164.9 ± 42.1 | 171.1 ± 39.2 | < 0.001 |
| HDL (mg/dl) | 36.0 ± 10.3 | 34.7 ± 8.9 | 36.4 ± 10.3 | 37.0 ± 11.6 | 35.9 ± 11.6 | 0.26 |
| LDL (mg/dl) | 108.8 ± 34.0 | 117.7 ± 36.3 | 112.2 ± 34.5 | 97.0 ± 28.2 | 98.7 ± 26.8 | < 0.001 |
| Uric acid (mg/dl) | 6.1 ± 1.8 | 6.0 ± 1.5 | 6.2 ± 1.7 | 6.0 ± 1.9 | 6.8 ± 2.2 | 0.08 |
| ALT (U/L) | 55.2 ± 108.9 | 55.6 ± 38.9 | 43.8 ± 35.7 | 70.4 ± 199.1 | 50.8 ± 68.5 | 0.21 |
| Hemoglobin (g%) | 14.2 ± 2.2 | 15.4 ± 1.5 | 14.5 ± 1.8 | 13.2 ± 2.1 | 11.4 ± 2.0 | < 0.001 |
| Sodium (mmol/L) | 139.0 ± 6.6 | 139.3 ± 3.3 | 139.4 ± 3.3 | 138.3 ± 11.3 | 138.4 ± 5.9 | 0.41 |
| Potassium (mmol/L) | 4.2 ± 0.6 | 4.2 ± 0.6 | 4.1 ± 0.6 | 4.2 ± 0.6 | 4.6 ± 0.8 | < 0.001 |
| Complication | ||||||
| Hypotension | 120 (23.4%) | 15 (9.2%) | 30 (17.5%) | 58 (42.6%) | 17 (40.5%) | < 0.001 |
| IABP use | 41 (8%) | 3 (1.8%) | 7 (4.1%) | 22 (16.2%) | 19 (21.4%) | < 0.001 |
| CAVB | 23 (4.5%) | 2 (1.2%) | 5 (2.9%) | 11 (8.1%) | 5 (11.9%) | 0.002 |
| Ventricular tachycardia | 24 (4.7%) | 5 (3.1%) | 3 (1.8%) | 12 (8.8%) | 4 (9.5%) | 0.009 |
| Respiratory failure | 66 (12.9%) | 4 (2.5%) | 14 (8.2%) | 35 (25.7%) | 13 (31%) | < 0.001 |
| Initial presentation | ||||||
| Heart rate | 81.9 ± 25.7 | 82.7 ± 17.0 | 77.7 ± 27.5 | 83.3 ± 27.1 | 88.2 ± 29.9 | 0.44 |
| SBP (mmHg) | 133.0 ± 34.7 | 137.1 ± 27.3 | 135.3 ± 35.8 | 125.2 ± 35.7 | 123.0 ± 47.9 | 0.02 |
| Killip classification | 1.97 ± 1.34 | 1.52 ± 0.91 | 1.85 ± 1.41 | 2.49 ± 1.46 | 2.46 ± 1.42 | 0.03 |
| Infarct-related vessels | ||||||
| Right coronary artery | 228 (44.5%) | 68 (41.7%) | 77 (45%) | 65 (47.8%) | 18 (42.9%) | 0.76 |
| Left circumflex artery | 29 (5.7%) | 8 (4.9%) | 8 (4.7%) | 11 (8.1%) | 2 (4.8%) | 0.56 |
| Left anterior descending artery | 255 (49.8%) | 87 (53.4%) | 86 (50.3%) | 60 (44.1%) | 22 (52.4%) | 0.44 |
| Triple-vessel disease | 34 (6.7%) | 11 (6.7%) | 16 (9.3%) | 10 (7.4%) | 4 (9.5%) | 0.86 |
| Post-MI LV function | 50.3 ± 11.1 | 53.1 ± 12.9 | 51.6 ± 13.0 | 48.7 ± 12.1 | 47.0 ± 10.9 | 0.05 |
Values are mean ± SD or number (%).
ALT, alanine aminotransferase; CAVB, complete atrio-ventricular block; HDL, high density lipoprotein; IABP, intra-aortic balloon pump; LDL, low density lipoprotein; Post-MI LV function, post-myocardial infarction left ventricular function; SBP, systolic blood pressure.
Stage 1: eGFR ≥ 90 mL/min/1.73 m2; stage 2: 90 > eGFR ≥ 60 mL/min/1.73 m2; stage 3: 60 > eGFR ≥ 30 mL/min/1.73 m2; stage 4: eGFR < 30 mL/min/1.73 m2.